We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

BeiGene Ltd (BGNE) ADR Each Representing 13 Ord Shares

Sell:$180.78 Buy:$181.37 Change: $3.18 (1.73%)
Market closed |  Prices as at close on 3 January 2025 | Switch to live prices |
Sell:$180.78
Buy:$181.37
Change: $3.18 (1.73%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 3 January 2025 | Switch to live prices |
Sell:$180.78
Buy:$181.37
Change: $3.18 (1.73%)
Market closed |  Prices as at close on 3 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Contact details

Address:
C/O Mourant Governance Services (Cayman)
94 Solaris Avenue, Camana Bay
GRAND CAYMAN
KY1-1108
Cayman Islands
Telephone:
+1 (345) 9494123
Website:
https://www.beigene.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BGNE
ISIN:
US07725L1026
Market cap:
$20.38 billion
Shares in issue:
1.27 billion
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Oyler
    Co-Founder, Executive Chairman of the Board, Chief Executive Officer
  • Xiaobin Wu
    President, Chief Operating Officer, General Manager - China
  • Xiaodong Wang
    Co-Founder, Non-Executive Director
  • Chan Lee
    Senior Vice President, General Counsel
  • Matthew Shaulis
    General Manager, North America
  • Lai Wang
    Global Head of R&D

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.